-
NovoCare Pharmacy Offers Reduced-Cost Wegovy for Cash-Paying Patients
•
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient delivery option designed to provide cash-paying patients with all dose strengths of Wegovy at a reduced cost of USD 499 per month. Program DetailsThe introduction of NovoCare Pharmacy mirrors the approach taken by US major…
-
Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics
•
US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with Eli Lilly & Co. (NYSE: LLY). The alliance aims to discover, develop, and commercialize molecular glue therapeutics in oncology. Collaboration DetailsSpecifically, Magnet’s TrueGlue discovery platform will be utilized to identify molecular glues capable of inducing…
-
Eli Lilly to Establish Four New US Pharma Manufacturing Sites
•
US major Eli Lilly & Co. (NYSE: LLY) announced plans to establish four new pharmaceutical manufacturing sites in the United States. The move aims to boost the company’s domestic medicine production across various therapeutic areas. API Manufacturing and Supply Chain StrengtheningThree of the new sites will focus on manufacturing active…
-
Eli Lilly Launches New Zepbound Doses with Lower Prices for Self-Pay Patients
•
Eli Lilly & Co. (NYSE: LLY) announced the launch of 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide) for self-pay patients with obesity, priced at USD 499 under the new Zepbound Self Pay Journey Program. Dosing OptionsThe program offers self-pay patients a range of Zepbound doses: 2.5 mg,…
-
Eli Lilly Acquires Organovo’s FXR Program for Inflammatory Bowel Disease
•
US-based Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical-stage biotech focused on inflammatory bowel disease (IBD), announced that its FXR program, including lead asset FXR314, has been acquired by Eli Lilly and Company (NYSE: LLY). The transaction grants Lilly global commercial and intellectual property rights to the program. Transaction DetailsUnder the…
-
Eli Lilly Expands Collaboration with AdvanCell on Targeted Alpha Therapies for Cancer
•
Eli Lilly & Co. (NYSE: LLY) has expanded its collaboration with Australia-based AdvanCell, a clinical-stage radiopharmaceutical company, to develop targeted alpha therapies for various cancers. The partnership will leverage AdvanCell’s Pb-212 production technology and Lilly’s drug development expertise. Collaboration DetailsThe agreement combines AdvanCell’s proprietary radionuclide infrastructure with Lilly’s drug candidate…
-
Eli Lilly Licenses OliX Pharma’s OLX75016 for MASH and Cardiometabolic Diseases
•
Eli Lilly & Co. (NYSE: LLY) has signed a licensing agreement with OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a South Korea-based RNAi therapeutics developer, to jointly develop and commercialize OLX75016, an investigational drug targeting metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications. Drug ProfileOLX75016, derived from a genome-wide association study (GWAS), is…
-
Eli Lilly’s Q4 Sales Soar 45% to $13.53B on Strength of GLP-1 Drugs
•
Eli Lilly & Co. (NYSE: LLY) reported a robust finish to 2024, with Q4 revenues climbing 45% year-on-year (YOY) to reach USD 13.53 billion. The surge was primarily fueled by its GLP-1 drugs Mounjaro and Zepbound (tirzepatide). Excluding these incretin-focused drugs, Lilly’s overall portfolio still expanded by 20% YOY. For…
-
Eli Lilly and Merck Launch Consortium for Innovative Drug Manufacturing
•
US-based Eli Lilly and Company (NYSE: LLY) and Merck & Co. Inc. (NYSE: MRK) have announced the launch of the Young Institute Pharmaceutical Manufacturing Consortium in collaboration with Purdue University. The initiative aims to develop new methods of drug manufacturing, driving technological innovation in the pharmaceutical industry. Consortium Focus and…
-
FDA Lifts Clinical Hold on Sanofi’s Cialis Over-the-Counter Trial
•
France-based Sanofi’s (NASDAQ: SNY, EPA: SAN) Consumer Healthcare unit Opella has announced that the US FDA has lifted a clinical hold on its planned Actual Use Trial (AUT) for Cialis (tadalafil). This move allows Sanofi to initiate the AUT and potentially switch the PDE5 inhibitor from a prescription to an…
-
Eli Lilly’s Omvoh Approved by FDA for Crohn’s Disease Treatment
•
US major Eli Lilly and Company (NYSE: LLY) has announced receiving marketing approval from the US FDA for its Omvoh (mirikizumab-mrkz), an interleukin-23p19 (IL-23p19) antagonist, to treat moderately to severely active Crohn’s disease in adults. This approval follows the FDA’s nod for its use as a first-in-class treatment for moderately…
-
a16z Bio + Health Launches Biotech Ecosystem Venture Fund
•
Andreessen Horowitz (a16z) Bio + Health has announced the establishment of the Biotech Ecosystem Venture Fund, a venture capital fund backed by Eli Lilly and Company (NYSE: LLY). The fund is designed to drive transformative progress in healthcare by investing in therapeutic platforms and cutting-edge technology companies that can bring…
-
Eli Lilly to Acquire Scorpion Therapeutics’ STX-478 for $2.5B
•
US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from its compatriot firm Scorpion Therapeutics, Inc. STX-478 is a mutant-selective PI3Kα inhibitor currently being studied in a Phase I/II clinical trial for the treatment of breast cancer and other advanced solid tumors. This strategic move…
-
Mediar Therapeutics and Eli Lilly Ink Deal for IPF Drug MTX-463
•
US-based clinical-stage biotech Mediar Therapeutics, Inc. has announced a global license agreement with Eli Lilly and Company (NYSE: LLY) to advance its investigational drug MTX-463 into a Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). This strategic partnership aims to further develop and potentially bring to…
-
Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion
•
US-based Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks with compatriot firm Scorpion Therapeutics, with the aim of acquiring the oncology biotech for a potential USD 2.5 billion. This strategic move is expected to significantly expand Eli Lilly’s presence in the oncology sector. Deal Details and TimelineAccording…
-
Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments
•
UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co. (NYSE: LLY) to discover novel therapeutic candidates for the treatment of amyotrophic lateral sclerosis (ALS). This alliance is designed to accelerate the development of up to five new therapies for this debilitating condition. Agreement DetailsUnder…
-
Eli Lilly China’s Neuroscience VP Jiang Yifei Departs for New Opportunities
•
Jiang Yifei, the current vice president of Eli Lilly (NYSE: LLY) China’s neuroscience division, has announced his departure to seek external development opportunities, according to local media. His last day in the role will be January 14, 2025. Career Highlights at Eli Lilly ChinaDuring his tenure at Eli Lilly China,…
-
Eli Lilly’s Zepbound Receives FDA Approval for Moderate-to-Severe OSA and Obesity
•
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has revealed that the US Food and Drug Administration (FDA) has granted another indication approval for its drug Zepbound (tirzepatide), marking it as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Zepbound can…
-
Eli Lilly’s Kisunla Receives NMPA Approval for Early Alzheimer’s Disease Treatment
•
Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its drug donanemab-azbt, marketed under the name Kisunla. The drug is administered as a 350 mg/20 mL injection every four weeks…
-
Innovent Biologics Partners with Eli Lilly for Distribution of Jaypirca in China
•
China-based Innovent Biologics, Inc. (HKG: 1801) has entered into a significant distribution and promotion agreement with US pharmaceutical giant Eli Lilly and Company (NYSE: LLY). The agreement pertains to Lilly’s non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, Jaypirca (pirtobrutinib). Financial details of the agreement have not been disclosed. Under the terms,…
